Combinatorial Antibody Synthesis for the Discovery of New Anti-Tumour Immunomodulators

Project description

A new technology for the synthesis of anti-cancer antibodies

The major drawback of cancer treatments is their non-selectivity, which leads to significant side effects. Harnessing the immune system to fight cancer has emerged as a promising therapeutic approach. The EU-funded BispecificsThatClick project is focussing on the development of bispecific antibodies that target two antigens, one on cancer cells and the other on immune cells, leading to the efficient killing of the former. Scientists have developed a novel methodology to speed up and improve the efficiency of bispecific antibody production. The generated library of antibodies will be subjected to extensive analysis to determine their mode of action and their anti-tumour efficacy.

Fields of science

• medical and health sciences › basic medicine › immunology
• medical and health sciences › clinical medicine › oncology

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2018 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2018

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

Net EU contribution

€ 212 933,76

Address

Trinity Lane The Old Schools
CB2 1TN Cambridge
United Kingdom

Region

East of England › East Anglia › Cambridgeshire CC

Activity type

Higher or Secondary Education Establishments

Links

Other funding

€ 0,00